Tetrahydrocarboline compounds as anticancer agents
申请人:Wang Weibo
公开号:US20050215580A1
公开(公告)日:2005-09-29
Tetrahydrocarboline compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the tetrahydrocarboline compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the tetrahydrocarboline compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
TETRAHYDROCARBOLINE COMPOUNDS AS ANTICANCER AGENTS
申请人:CHIRON CORPORATION
公开号:EP1706404A2
公开(公告)日:2006-10-04
US7855295B2
申请人:——
公开号:US7855295B2
公开(公告)日:2010-12-21
The discovery of tetrahydro-β-carbolines as inhibitors of the kinesin Eg5
作者:Paul A. Barsanti、Weibo Wang、Zhi-Jie Ni、David Duhl、Nathan Brammeier、Eric Martin、Dirksen Bussiere、Annette O. Walter
DOI:10.1016/j.bmcl.2009.11.012
日期:2010.1
A series of tetrahydro-beta-carbolines were identified by HTS as inhibitors of the kinesin Eg5. Molecular modeling and medicinal chemistry techniques were employed to explore the SAR for this series with a focus of removing potential metabolic liabilities and improving cellular potency. (C) 2009 Elsevier Ltd. All rights reserved.
[EN] TETRAHYDROCARBOLINE COMPOUNDS AS ANTICANCER AGENTS<br/>[FR] COMPOSES DE TETRAHYDROCARBOLINE COMME AGENTS ANTICANCEREUX